"Karyopharm Therapeutics Inc. (KPTI) reported its Q2 2025 earnings, highlighting ongoing financial challenges and a cautious outlook, which analysts have valued at approximately $25.92 per share. The overall sentiment remains subdued, reflecting concerns over the company's ability to navigate its financial landscape effectively."